Clinical trials: Post-exposure Prophylaxis
Leprosy
Post ExpOsure Prophylaxis for LEprosy in the Comoros and Madagascar
This is a cluster randomized trial on effectiveness of different modalities of Single Double Dose of Rifampicin Post-Exposure Prophylaxis (SDDR-PEP) for leprosy in the Comoros (Anjouan and Mohéli) and Madagascar.
- Trial name
- PEOPLE (NCT03662022)
- Testing
- Rifampicin
- Where
- 3 sites in Comoros, Madagascar
- Volunteers
- 144,000 people, healthy volunteers welcome
- Sponsor
- Institute of Tropical Medicine, Belgium
Graft Versus Host Disease, Hematologic Neoplasms
Optimizing PTCy Dose and Timing
Background: Stem cell or bone marrow transplants can cure or control blood cancers. Sometimes the donor cells see the recipient's body as foreign. This can cause complications.
- Trial name
- NCT03983850
- Testing
- Busulfan, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Influenza, Human, Respiratory Tract Infections
A Study to Confirm Efficacy of a Single Dose of Baloxavir Marboxil in the Post-exposure Prophylaxis (PEP) of Influenza Virus Infection in Chinese Participants
The main purpose of the study is to evaluate the efficacy of a single dose of baloxavir marboxil compared with placebo in the PEP of influenza virus infection with respect to symptomatic, laboratory-confirmed influenza in…
- Conditions
- Influenza, Human, Respiratory Tract Infections, Post-exposure Prophylaxis
- Trial name
- Pearlstone (NCT07827599)
- Testing
- Baloxavir marboxil
- Where
- 8 sites in China
- Volunteers
- 325 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
HIV Infections
Behavioral, Clinical and Basic Science Studies of Non-occupational Post-exposure Prophylaxis ("PEP-2")
This is a randomized trial to compare the effect of standard versus enhanced risk reduction counseling on risk behavior incidence in individuals receiving PEP medications.
- Trial name
- PEP-2 (NCT00473018)
- Testing
- standard versus enhanced risk reduction counseling
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Rabies
Randomized Phase II Trial on Safety and Neutralizing Activity of CL184 and Rabies Vaccine Versus Human Rabies Immune Globulin (HRIG) and Rabies Vaccine in Children and Adolescents
The aim of this study is to evaluate the safety of the monoclonal antibody cocktail CL184 in combination with rabies vaccine compared with human rabies immune globulin (HRIG) in combination with rabies vaccine in healthy children…
- Trial name
- NCT00708084
- Testing
- CL184, HRIG
- Where
- Philippines
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Leprosy
Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy (Phase 2)
This study will evaluate a combination of bedaquiline and rifampicin as post exposure prophylaxis (PEP) for leprosy in Comoros. It will be a follow-up to the PEOPLE trial on PEP with rifampicin, which is ending in 2022.
- Trial name
- BE-PEOPLE P2 (NCT05406479)
- Testing
- BE-PEP (Bedaquiline), SDR-PEP, BE-PEP (Rifampicine)
- Where
- Comoros
- Volunteers
- 313 people, healthy volunteers welcome
- Sponsor
- Institute of Tropical Medicine, Belgium
Unmet Need for Contraception, Uptake of HIV Prevention
Mobile Health Supported Self-care Among Tertiary Education Students in Zimbabwe
Young people of ages 15-24 years, particularly those in Sub-Saharan Africa, do not optimally take up HIV services (HIV testing, HIV prevention and HIV treatment) and contraception.
- Conditions
- Unmet Need for Contraception, Uptake of HIV Prevention, Healthy Participants
- Trial name
- MASCOT (NCT07403318)
- Testing
- MASCOT
- Where
- Zimbabwe
- Volunteers
- 16,000 people, healthy volunteers welcome
- Sponsor
- Liverpool School of Tropical Medicine
Influenza, Influenza Prophylaxis
Oseltamivir and Baloxavir Marboxil for Prophylaxis Against Influenza Under a Hospital-based Setting
This study aims to randomly assign close contacts of hospitalized influenza virus patients to receive baloxavir marboxil prophylaxis, oseltamivir prophylaxis or no antiviral prophylaxis and monitor the incidence of clinical…
- Conditions
- Influenza, Influenza Prophylaxis, Nosocomial Infection
- Trial name
- NCT06762587
- Testing
- Baloxavir Marboxil, Oseltamivir
- Where
- China
- Volunteers
- 372 people, healthy volunteers welcome
- Sponsor
- Capital Medical University
Relapsing Fever, Tick-borne, Jarisch Herxheimer Reaction
Post Exposure Treatment With Doxycycline for the Prevention of Relapsing Fever
Abstract Background Tick-Borne Relapsing Fever (TBRF) is an acute febrile illness. In Israel, TBRF is caused by Borrelia persica and is transmitted by Ornithodoros tholozani ticks.
- Trial name
- NCT00237016
- Testing
- doxycycline treatment
- Where
- Israel
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Medical Corps, Israel Defense Force
Leprosy
Novel Interventions and Diagnostic Tests for Leprosy
Contact with Mycobacterium leprae (M. leprae) infected individuals is a risk factor for development of leprosy. Thus, detection of asymtomatically M.
- Trial name
- INDIGO#2 (NCT06222372)
- Testing
- Rifampin
- Where
- Bangladesh
- Volunteers
- 1,100 people, healthy volunteers welcome
- Sponsor
- Annemieke Geluk
Virus Diseases, Rabies
A Phase 3 Clinical Trial to Evaluate Long-term Immunogenicity and Boostability of Purified Chick-Embryo Cell Rabies Vaccine in Adults Following Primary Series of Pre/Exposure Prophylaxis.
The aim of this study is to evaluate the long-term (up to approx.10 years) persistence and to assess the boostability of immune responses in participants who received a primary series of accelerated or conventional rabies PrEP IM…
- Trial name
- NCT02545517
- Testing
- Rabipur, Blood sampling, Purified Chick-Embryo Cell Rabies Vaccine
- Where
- 7 sites in Austria, Germany and 1 more
- Volunteers
- 459 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Human Immunodeficiency Virus (HIV)
ComBaCaL HIV Prevention TwiCs
This cluster-randomized intervention is embedded in the ComBaCaL (Community-Based Chronic disease care Lesotho) cohort study (EKNZ ID AO_2022-00058, clinicaltrials.gov ID NCT05596773, Lesotho NH-REC ID 210-2022), a platform for…
- Trial name
- CoPrev (NCT07581600)
- Testing
- CoPrev model, Referral to the nearest responsible health facility
- Where
- 2 sites in Lesotho, Switzerland
- Volunteers
- healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Rabies (Healthy Volunteers)
Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post-Exposure Prophylaxis in Adult and Pediatric Population in Thaïland
Primary Objective: To describe the immune response induced by VRVg-2 and Verorab vaccine at Day 14 (to assess the immune response after 3 doses [2-2-2]) and Day 42 (to assess the immune response after 4 doses [2-2-2-0-2]) when…
- Trial name
- NCT04478084
- Testing
- Purified vero rabies vaccine - serum free VRVg-2, Purified inactivated rabies vaccine, Equine rabies immunoglobulins (ERIG) (only Group 3 and Group 4)
- Where
- 3 sites in Thailand
- Volunteers
- 403 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Rabies Post-exposure Prophylaxis
Immunogenicity Assessment of Subjects Receiving Rabies Post-exposure Prophylaxis in Cambodia
A rabies virus neutralizing antibody (RVNA) concentration ≥ 0.5 IU/ml at 14 days after immunization is considered a proxy for protection in vaccine efficacy studies.
- Trial name
- NCT05684185
- Testing
- Intramuscular (IM) rabies post-exposure prophylaxis, Intradermal (ID) rabies post-exposure prophylaxis
- Where
- Cambodia
- Volunteers
- 215 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur du Cambodge
Rabies Prevention
Early Rabies Vaccine Immunization in Primary School Children
700 male and female healthy school-children (age 5 to 8) in Thailand were randomized to receive 2 or 3 primary rabies vaccine doses (PCECV, Rabipur) given intradermally in a dose of 0.1mL into the skin in the deltoid region.
- Trial name
- I49P1 (NCT01107275)
- Testing
- rabies vaccine
- Where
- Thailand
- Volunteers
- 703 people, healthy volunteers welcome
- Sponsor
- Provincial Public Health Office, Phetchabun
Pregnancy Related
EMBRACE (Evaluation of Maternal and Baby Outcome Registry After Chemoprophylactic Exposure)
The Prevention Agent Pregnancy Exposure Registry, also known as EMBRACE (Evaluation of Maternal and Baby Outcome Registry After Chemoprophylactic Exposure) is a prospective observational cohort investigation of exposures to study…
- Trial name
- EMBRACE (NCT01209754)
- Where
- 17 sites in United States, South Africa and 2 more
- Volunteers
- 873 people, healthy volunteers welcome
- Sponsor
- Microbicide Trials Network
Virus Diseases
A Study to Evaluate Persistence of Immune Responses After Post-exposure Prophylaxis of Rabipur® (Purified Chicken-embryo Cell Rabies Vaccine) in Chinese Children
The purpose of this study is to evaluate the long-term persistence of immune responses approximately 5 years or more after simulated rabies post-exposure prophylaxis provided in 2012 according to Essen (1-1-1-1-1) or Zagreb…
- Trial name
- NCT02991872
- Testing
- Blood draw
- Where
- China
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Rabies Post-exposure Prophylaxis
SYN023 With Rabies Vaccine in Healthy Pediatric Subjects
This study is a randomized, double-blind, active-controlled design. The goal is to evaluate the safety, pharmacokinetics and pharmacodynamic of SYN023 in combination with rabies vaccine in healthy participants under 18 years of…
- Trial name
- NCT07342257
- Testing
- SYN023, Rabies Vaccine, HRIG
- Where
- China
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Synermore Biologics (Suzhou) Co., Ltd.
HIV Infections
A Study of Zidovudine in the Prevention of HIV Infection in Individuals Exposed to the Virus
To prevent individuals who have had a massive accidental exposure to HIV from becoming infected with HIV and possibly developing AIDS, by treating them with zidovudine (AZT).
- Trial name
- NCT00000993
- Testing
- Zidovudine
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV, STIs
Combatting HIV Or Other STIs Early (CHOOSE)
The overarching goal of this project is to optimize the PrEP Choice integrated mHealth package and assess the efficacy and cost of PrEP Choice on PrEP initiation and adherence among young people.
- Conditions
- HIV, STIs, STIs Prevention, HIV Prevention
- Trial name
- CHOOSE (NCT07510048)
- Testing
- Standard of care and PrEP Choice at Enrollment, Standard of care followed by PrEP Choice at Month 9
- Where
- 6 sites in United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Westat